A Randomization, Double-blind, Active-controlled, Multicenter, Phase 3 Trial to Evaluate the Efficacy and Safety of AD-224A and AD-224B in Patients with Essential Hypertension
Overview
- Phase
- Phase 3
- Intervention
- AD-224B
- Conditions
- Hypertension,Essential
- Sponsor
- Addpharma Inc.
- Enrollment
- 252
- Locations
- 1
- Primary Endpoint
- Change rate of MSSBP
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of AD-224
Detailed Description
Condition or disease : Essential Hypertension
Investigators
Eligibility Criteria
Inclusion Criteria
- •Signed informed consent
- •Patients with Essential Hypertension
- •Other inclusions applied
Exclusion Criteria
- •Patient with Secondary Hypertension
- •Other exclusions applied
Arms & Interventions
AD-224B
Placebo of AD-224A+AD-224B+Placebo of AD-224C
Intervention: AD-224B
AD-224B
Placebo of AD-224A+AD-224B+Placebo of AD-224C
Intervention: Placebo of AD-224A
AD-224B
Placebo of AD-224A+AD-224B+Placebo of AD-224C
Intervention: Placebo of AD-224C
AD-224C
Placebo of AD-224A+Placebo of AD-224B+AD-224C
Intervention: AD-224C
AD-224C
Placebo of AD-224A+Placebo of AD-224B+AD-224C
Intervention: Placebo of AD-224A
AD-224C
Placebo of AD-224A+Placebo of AD-224B+AD-224C
Intervention: Placebo of AD-224B
AD-224A
AD-224A+Placebo of AD-224B+Placebo of AD-224C
Intervention: AD-224A
AD-224A
AD-224A+Placebo of AD-224B+Placebo of AD-224C
Intervention: Placebo of AD-224B
AD-224A
AD-224A+Placebo of AD-224B+Placebo of AD-224C
Intervention: Placebo of AD-224C
Outcomes
Primary Outcomes
Change rate of MSSBP
Time Frame: Baseline, Week 8
Change from baseline in mean sitting systolic blood pressure